[PDF][PDF] Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
EA Olsen, YH Kim, TM Kuzel, TR Pacheco… - Journal of clinical …, 2007 - researchgate.net
Journal of clinical oncology, 2007•researchgate.net
Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment
Refractory Cutaneous T-Cell Lym Page 1 Phase IIB Multicenter Trial of Vorinostat in Patients
With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma Elise A.
Olsen, Youn H. Kim, Timothy M. Kuzel, Theresa R. Pacheco, Francine M. Foss, Sareeta Parker,
Stanley R. Frankel, Cong Chen, Justin L. Ricker, Jean Marie Arduino, and Madeleine Duvic A
B S T R A C T Purpose To evaluate the activity and safety of the histone deacetylase inhibitor …
Refractory Cutaneous T-Cell Lym Page 1 Phase IIB Multicenter Trial of Vorinostat in Patients
With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma Elise A.
Olsen, Youn H. Kim, Timothy M. Kuzel, Theresa R. Pacheco, Francine M. Foss, Sareeta Parker,
Stanley R. Frankel, Cong Chen, Justin L. Ricker, Jean Marie Arduino, and Madeleine Duvic A
B S T R A C T Purpose To evaluate the activity and safety of the histone deacetylase inhibitor …
Purpose
To evaluate the activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in persistent, progressive, or recurrent mycosis fungoides or Sézary syndrome (MF/SS) cutaneous t-cell lymphoma (CTCL) subtypes.
researchgate.net